Qiagen (NYSE:QGEN), a German provider of sample and assay technologies, has received emergency use authorisation for a new COVID-19 test from the US drugs regulator FDA, Reuters news agency reported on Monday.

The company was quoted as stating: "This polymerase chain reaction (PCR) multiplex test will be an important tool now and in upcoming winter seasons for simultaneous qualitative detection and differentiation of influenzas A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections within 80 minute."